Klaria signs exclusive development, license and supply agreements with Purdue Pharma (Canada) for the emergency treatment of anaphylactic reactions
Klaria has signed exclusive agreements with Purdue Pharma (Canada) for the development, licensing and manufacture of an emergency treatment for severe allergic reactions.Uppsala, Sweden and Pickering, Canada, 22 January, 2019 – Klaria AB (Klaria) (Parent Company, Klaria Pharma Holding AB, Stockholm OMX Nasdaq:KLAR) and Purdue Pharma (Canada) today announced they have entered into an exclusive development agreement for KL-01401 (Epinephrine Oromucosal Film). KL-01401 is a developmental stage formulation of epinephrine for emergency treatment of severe anaphylactic reactions in patients who